Tarlatamab
- Generic Name
- Tarlatamab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2307488-83-9
- Unique Ingredient Identifier
- 74X82ST8Q1
- Associated Conditions
- -
- Associated Therapies
- -
A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 41
- Registration Number
- NCT04702737
- Locations
- 🇺🇸
Community Health Network MD Anderson Cancer Center - North, Indianapolis, Indiana, United States
🇦🇺Chris OBrien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 269
- Registration Number
- NCT03319940
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center - Thoracic Oncology Clinic, Columbus, Ohio, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇦🇹Landeskrankenhaus Salzburg, Salzburg, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath